218 related articles for article (PubMed ID: 25274443)
1. Phase II evaluation of VDC-1101 in canine cutaneous T-cell lymphoma.
Morges MA; Burton JH; Saba CF; Vail DM; Burgess KE; Thamm DH
J Vet Intern Med; 2014; 28(5):1569-74. PubMed ID: 25274443
[TBL] [Abstract][Full Text] [Related]
2. Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma.
Thamm DH; Vail DM; Post GS; Fan TM; Phillips BS; Axiak-Bechtel S; Elmslie RS; Klein MK; Ruslander DA
J Vet Intern Med; 2017 May; 31(3):872-878. PubMed ID: 28370378
[TBL] [Abstract][Full Text] [Related]
3. Rabacfosadine for relapsed canine B-cell lymphoma: Efficacy and adverse event profiles of 2 different doses.
Saba CF; Vickery KR; Clifford CA; Burgess KE; Phillips B; Vail DM; Wright ZM; Morges MA; Fan TM; Thamm DH
Vet Comp Oncol; 2018 Mar; 16(1):E76-E82. PubMed ID: 28891260
[TBL] [Abstract][Full Text] [Related]
4. GS-9219/VDC-1101--a prodrug of the acyclic nucleotide PMEG has antitumor activity in spontaneous canine multiple myeloma.
Thamm DH; Vail DM; Kurzman ID; Babusis D; Ray AS; Sousa-Powers N; Tumas DB
BMC Vet Res; 2014 Jan; 10():30. PubMed ID: 24460928
[TBL] [Abstract][Full Text] [Related]
5. Concurrent use of rabacfosadine and L-asparaginase for relapsed or refractory multicentric lymphoma in dogs.
Cawley JR; Wright ZM; Meleo K; Post GS; Clifford CA; Vickery KR; Vail DM; Bergman PJ; Thamm DH
J Vet Intern Med; 2020 Mar; 34(2):882-889. PubMed ID: 32064697
[TBL] [Abstract][Full Text] [Related]
6. Outcomes and prognostic factors in canine epitheliotropic and nonepitheliotropic cutaneous T-cell lymphomas.
Azuma K; Ohmi A; Goto-Koshino Y; Tomiyasu H; Ohno K; Chambers JK; Uchida K; Namba H; Nagata M; Nagamine E; Nibe K; Irie M; Tsujimoto H
Vet Comp Oncol; 2022 Mar; 20(1):118-126. PubMed ID: 34250731
[TBL] [Abstract][Full Text] [Related]
7. Tanovea® for the treatment of lymphoma in dogs.
De Clercq E
Biochem Pharmacol; 2018 Aug; 154():265-269. PubMed ID: 29778492
[TBL] [Abstract][Full Text] [Related]
8. Rabacfosadine for naïve canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials.
Saba CF; Clifford C; Burgess K; Phillips B; Vail D; Wright Z; Curran K; Fan T; Elmslie R; Post G; Thamm D
Vet Comp Oncol; 2020 Dec; 18(4):763-769. PubMed ID: 32346934
[TBL] [Abstract][Full Text] [Related]
9. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.
Prince HM; Duvic M; Martin A; Sterry W; Assaf C; Sun Y; Straus D; Acosta M; Negro-Vilar A
J Clin Oncol; 2010 Apr; 28(11):1870-7. PubMed ID: 20212249
[TBL] [Abstract][Full Text] [Related]
10. Alternating rabacfosadine and doxorubicin for treatment of naïve canine lymphoma.
Saba CF; Fan TM; Phillips BS; Wright ZM; Thamm DH
Vet Comp Oncol; 2024 Jun; 22(2):278-283. PubMed ID: 38616055
[TBL] [Abstract][Full Text] [Related]
11. Multicenter, randomized, double-blinded, placebo-controlled study of rabacfosadine in dogs with lymphoma.
Weishaar KM; Wright ZM; Rosenberg MP; Post GS; McDaniel JA; Clifford CA; Phillips BS; Bergman PJ; Randall EK; Avery AC; Thamm DH; Christman Hull AA; Gust CM; Donoghue AR
J Vet Intern Med; 2022 Jan; 36(1):215-226. PubMed ID: 34952995
[TBL] [Abstract][Full Text] [Related]
12. Canine cutaneous epitheliotropic T-cell lymphoma: a review.
Fontaine J; Bovens C; Bettenay S; Mueller RS
Vet Comp Oncol; 2009 Mar; 7(1):1-14. PubMed ID: 19222826
[TBL] [Abstract][Full Text] [Related]
13. T-cell receptor gene rearrangement in canine mycosis fungoides: further support for a canine model of cutaneous T-cell lymphoma.
Fivenson DP; Saed GM; Beck ER; Dunstan RW; Moore PF
J Invest Dermatol; 1994 Feb; 102(2):227-30. PubMed ID: 7906287
[TBL] [Abstract][Full Text] [Related]
14. Is CCNU (lomustine) valuable for treatment of cutaneous epitheliotropic lymphoma in dogs? A critically appraised topic.
Laprais A; Olivry T
BMC Vet Res; 2017 Feb; 13(1):61. PubMed ID: 28222789
[TBL] [Abstract][Full Text] [Related]
15. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
Vu K; Wu CH; Yang CY; Zhan A; Cavallone E; Berry W; Heeter P; Pincus L; Wieduwilt MJ; William BM; Andreadis C; Kaplan LK; McCormick F; Porcu P; Brammer JE; Ai WZ
Clin Cancer Res; 2020 Mar; 26(5):1000-1008. PubMed ID: 31772119
[TBL] [Abstract][Full Text] [Related]
16. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome).
Dummer R; Duvic M; Scarisbrick J; Olsen EA; Rozati S; Eggmann N; Goldinger SM; Hutchinson K; Geskin L; Illidge TM; Giuliano E; Elder J; Kim YH
Ann Oncol; 2014 Sep; 25(9):1807-1812. PubMed ID: 24948692
[TBL] [Abstract][Full Text] [Related]
17. Photopheresis in cutaneous T-cell lymphoma: five-year experience.
Crovetti G; Carabelli A; Berti E; Guizzardi M; Fossati S; De Filippo C; Bertani E
Int J Artif Organs; 2000 Jan; 23(1):55-62. PubMed ID: 12118838
[TBL] [Abstract][Full Text] [Related]
18. Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphoma.
Vail DM; Thamm DH; Reiser H; Ray AS; Wolfgang GH; Watkins WJ; Babusis D; Henne IN; Hawkins MJ; Kurzman ID; Jeraj R; Vanderhoek M; Plaza S; Anderson C; Wessel MA; Robat C; Lawrence J; Tumas DB
Clin Cancer Res; 2009 May; 15(10):3503-10. PubMed ID: 19417014
[TBL] [Abstract][Full Text] [Related]
19. Treatment of canine cutaneous epitheliotropic T-cell lymphoma with oclacitinib: a case report.
Aslan J; Shipstone MA; Sullivan LM
Vet Dermatol; 2021 Aug; 32(4):398-e113. PubMed ID: 34033147
[TBL] [Abstract][Full Text] [Related]
20. Extracorporeal photophoresis: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(6):1-82. PubMed ID: 23074497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
